Cargando…
Structure of CTLA-4 complexed with a pH-sensitive cancer immunotherapeutic antibody
Autores principales: | Gao, Han, Cai, Haiyan, Liu, Jia, Wang, Xiaoxiao, Zheng, Pan, Devenport, Martin, Xu, Ting, Dou, Fei, Liu, Yang, Zhou, Aiwu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7606454/ https://www.ncbi.nlm.nih.gov/pubmed/33298884 http://dx.doi.org/10.1038/s41421-020-00202-9 |
Ejemplares similares
-
Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice
por: Du, Xuexiang, et al.
Publicado: (2018) -
Hijacking antibody-induced CTLA-4 lysosomal degradation for safer and more effective cancer immunotherapy
por: Zhang, Yan, et al.
Publicado: (2019) -
Conditionally Active, pH-Sensitive Immunoregulatory Antibodies Targeting VISTA and CTLA-4 Lead an Emerging Class of Cancer Therapeutics
por: Smith, F. Donelson, et al.
Publicado: (2023) -
Diverse Mechanisms Regulate the Surface Expression of Immunotherapeutic Target CTLA-4
por: Schneider, Helga, et al.
Publicado: (2014) -
Structural mechanism of VWF D’D3 dimer formation
por: Shu, Zimei, et al.
Publicado: (2022)